Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.

Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression of latent tuberculosis infection into active TB disease. Treatment options include the following.

  • Isoniazid (INH) daily for nine months
  • INH and Rifapentine (RPT) once weekly for three months under direct observation
  • Rifampin (RIF) daily for four months

Active TB Disease: Treatment for active TB usually involves a two-phase approach.

  • Initial Phase: This involves taking four medications—Isoniazid (INH), Rifampin (RIF), Ethambutol (EMB), and Pyrazinamide (PZA)—for two months. The precise regimen may be adjusted based on the patient's response to treatment and the strain of TB.
  • Continuation Phase: This phase lasts at least four months and typically involves taking INH and RIF.

Further, drug-resistant tuberculosis includes multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.

  • Multidrug-resistant tuberculosis is a form of disease that does not respond to at least INH and RIF, the two most potent anti-TB drugs.
  • Extensively drug-resistant tuberculosis represents an advanced stage of multidrug-resistant TB, with resistance not only to fluoroquinolone categories but also to at least one of three injectable second-line medications.

Treatment for these forms of TB must be individualized and typically involve a longer duration of therapy. When first-line drugs fail to eradicate the bacteria that cause TB, more second-line drugs are used to treat tuberculosis. These include fluoroquinolones such as levofloxacin and moxifloxacin and aminoglycosides such as streptomycin, ethambutol, and cycloserine.

It is essential that a healthcare professional supervise all tuberculosis patients, ensuring strict adherence to the prescribed treatment to prevent drug resistance and treatment ineffectiveness. In a hospital setting, TB patients must be placed on droplet precautions, with healthcare providers wearing a gown, gloves, an N95 mask, and protective eyewear. Additionally, patients should be housed in a negative pressure room or a room equipped with a HEPA filter.

Additionally, Directly Observed Therapy (DOT) is a strategy for monitoring tuberculosis treatment. This approach involves healthcare providers or trained health workers watching patients take their TB medications to ensure adherence. DOT can be administered in various settings, including clinics, hospitals, and the patient's home.

Proper nutrition and infection control measures are also essential for successful TB treatment. Following a well-rounded diet abundant in essential vitamins, minerals, and protein can fortify the immune system and facilitate recovery. It is also necessary to maintain good hygiene and follow proper cough etiquette, which is vital for TB patients to prevent disease transmission to others.

Finally, regular follow-up and monitoring are crucial components of TB treatment. Patients should undergo monthly sputum culture testing to ensure they respond well to treatment, and a healthcare provider should promptly address any side effects or complications. With proper medical management and support, TB can be successfully treated and cured. Individuals with latent or active TB need to seek medical care and follow their prescribed treatment regimen, not only to protect their health, but also to prevent the spread of this infectious disease.

Dal capitolo 3:

article

Now Playing

3.10 : Pulmonary Tuberculosis V

Lower Respiratory Tract Infections

48 Visualizzazioni

article

3.1 : Polmonite I: Introduzione

Lower Respiratory Tract Infections

113 Visualizzazioni

article

3.2 : Polmonite II: fisiopatologia

Lower Respiratory Tract Infections

107 Visualizzazioni

article

3.3 : Polmonite III: complicanze e valutazione

Lower Respiratory Tract Infections

66 Visualizzazioni

article

3.4 : Polmonite IV: Gestione

Lower Respiratory Tract Infections

150 Visualizzazioni

article

3.5 : Polmonite V: Gestione infermieristica e prevenzione

Lower Respiratory Tract Infections

1.2K Visualizzazioni

article

3.6 : Tubercolosi polmonare I

Lower Respiratory Tract Infections

86 Visualizzazioni

article

3.7 : Tubercolosi polmonare II

Lower Respiratory Tract Infections

91 Visualizzazioni

article

3.8 : Tubercolosi polmonare III

Lower Respiratory Tract Infections

131 Visualizzazioni

article

3.9 : Tubercolosi polmonare IV

Lower Respiratory Tract Infections

63 Visualizzazioni

article

3.11 : Insufficienza respiratoria acuta-I

Lower Respiratory Tract Infections

80 Visualizzazioni

article

3.12 : Insufficienza respiratoria acuta-II

Lower Respiratory Tract Infections

74 Visualizzazioni

article

3.13 : Insufficienza respiratoria acuta-III

Lower Respiratory Tract Infections

78 Visualizzazioni

article

3.14 : Insufficienza respiratoria acuta-IV

Lower Respiratory Tract Infections

58 Visualizzazioni

article

3.15 : Insufficienza respiratoria acuta-V

Lower Respiratory Tract Infections

45 Visualizzazioni

JoVE Logo

Riservatezza

Condizioni di utilizzo

Politiche

Ricerca

Didattica

CHI SIAMO

Copyright © 2025 MyJoVE Corporation. Tutti i diritti riservati